Chronic News and Research

RSS

Exercise is effective for treating chronic shoulder pain

Supervised exercises are more effective than shockwave treatment to relieve chronic shoulder pain, finds a study published on bmj.com today.

16 Sep 2009

Findings could lead to new neurological treatments

The power of the imagination is well-known: it's no surprise that scary music is scarier with your eyes closed. But now neuroscientist and psychiatrist Prof. Talma Hendler of Tel Aviv University's Functional Brain Center says that this phenomenon may open the door to a new way of treating people with Alzheimer's, Parkinson's and other neurological diseases.

16 Sep 2009

Aviva Select series of Disease Management and Wellness programs launched

Avivia Health announces Avivia Select, a new series of affordable Disease Management and Wellness programs specifically designed to help companies provide important new benefits to their employees. Avivia Health is the only national provider of Disease Management and Wellness Solutions based on 60 years of evidence-based care by parent organization Kaiser Permanente.

16 Sep 2009

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection.

16 Sep 2009

iMedicor and Transgenomic to develop an educational marketing program for NuroPro

iMedicor and Transgenomic today announced that they have signed an agreement to develop an educational marketing program for NuroPro, Transgenomic’s diagnostic tests for Alzheimer’s and Parkinson’s disease.

15 Sep 2009

Mantra medicine tool helps patients in healing process

Dr. Mitchell Earl Gibson, a board-certified medical doctor in High Point, North Carolina, has formed a company that creates mantra and prayer-meditation-based recordings.

15 Sep 2009

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

A study exploring the healing of diabetic skin ulcers using topical oxygen/ozone gas mixtures could not proceed to completion and was now abandoned, according to Ozonics International, LLC, a veteran-owned biotechnology company engaged in the research and development of ozone-based medical therapies.

15 Sep 2009

HealthInsight unveils value-based solutions to reduce health care costs

HealthInsight, provider of the only value-based health care administration platform, officially unveils a set of technology and services for health insurers, third-party administrators and employers that are proven to lower overall medical costs while improving the quality of care. The new platform will be used to determine and track health actions that are directly tied to benefit designs, which is instrumental in lowering health care costs.

15 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

Less than five percent of employers plan to reduce health and productivity programs: IBI

Today the non-profit Integrated Benefits Institute (IBI) released a preliminary result from a survey of more than 400 employers indicating that less than five percent plan to reduce or eliminate health and productivity programs. This flies in the face of recent reports that employers are likely to eliminate wellness programs as a cost-saving measure.

15 Sep 2009

Wake Pharma to present clinical evidence in the treatment of wounds using Wound-Be-Gone at SAWC

Wake Pharma US announced today that clinical evidence in the treatment of wounds using Wound-Be-Gone® will be presented at the fall Society for Advance Wound Care Conference. The SAWC is being held in Washington, DC from September 16-18, 2009. The clinical evidence and data will be presented through posters on display during the meeting.

15 Sep 2009

Gentic circuits that cause mucous hyper-production identified

Scientists have identified the main genetic switch that causes excessive mucous in the lungs, a discovery that one day could ease suffering for people with chronic lung diseases like asthma and cystic fibrosis, or just those fighting the common cold.

15 Sep 2009

Somatic Systems accelerates efforts on projects to provide pain care services to the US Military

Somatic Systems, Inc. (PINKSHEETS: SMAS) stated that they have accelerated their efforts on their projects to provide pain care services to the US Military and establish Military health insurance coverage for Somatic Systems' powerful Clinical Somatics pain treatment method.

15 Sep 2009

LLS to invest in research to reduce toxic side-effects of cancer treatment

The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life-threatening, but always unacceptably reducing a patient's quality of life.

15 Sep 2009

Stem cell therapy holds great promise for regenerative medicine

The recipients of The 2009 Lasker Awards, announced today, represent the dramatic advances achieved in biotechnology research that have led to a revolutionary cancer treatment and the tremendous promise of stem cell therapy for regenerative medicine. Such advances portend a potential $700 million global market for new therapies within less than five years, according to Genetic Engineering & Biotechnology News (GEN, www.genengnews.com).

15 Sep 2009

Misonix receives donation from anonoymous patient to buy SonicOne ultrasonic wound care system

Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced that a patient, who wishes to remain anonymous, donated the majority of the funds necessary for Christus St. Vincent Medical Center, Santa Fe, NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement System. The System was shipped and installed during the second half of August 2009.

15 Sep 2009

Dominion develops and validates clinical quantitative assays for tapentadol

Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

15 Sep 2009